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COLORECTAL CANCER: A LITERATURE REVIEW 
PATRICK CALLAN 
 
ABSTRACT: 
Colorectal cancer (CRC) is a cancer caused by uncontrolled cell growth in the 
colon, rectum, or appendix. It has been shown through genetic analysis that can-
cers of the colon and rectum are genetically the same. Symptoms of these types 
of cancers include rectal bleeding and anemia. These symptoms are sometimes 
associated with weight loss or bowel changes. Colorectal cancers generally pro-
gress due to environmental factors, one’s lifestyle and increasing age. Very few 
cases are associated with genetic disorders. Inflammatory conditions have also 
been shown to favor the development of CRC; patients with inflammatory bowel 
disease have an annual risk increase of 1% per year. Despite improvements in 
screening, detection, and treatment, CRC is currently the third most common 
cancer, and accounts for over 1 million diagnoses and half a million deaths per 
year, which is equivalent to approximately 8% of cancer-related deaths world-
wide. This review will discuss several factors of colorectal cancer, including risk 
factors, genes involved, incidence, and mortality. And in doing so, it will become 
obvious that more efforts must be made into research of colorectal cancer, and 
public health education about the risk factors of the disease. 
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INTRODUCTION 
Colorectal cancer (CRC) is a cancer caused by uncontrolled cell growth in the 
colon, rectum, or appendix. It has been shown through genetic analysis that can-
cers of the colon and rectum are genetically the same. Symptoms of these types 
of cancers include rectal bleeding and anemia. These symptoms are sometimes 
associated with weight loss or bowel changes. Colorectal cancers generally pro-
gress due to environmental factors, one’s lifestyle and increasing age. Very few 
cases are associated with genetic disorders. Inflammatory conditions have also 
been shown to favor the development of CRC; patients with inflammatory bowel 
disease have an annual risk increase of 1% per year. Despite improvements in 
screening, detection, and treatment, CRC is currently the third most common 
cancer, and accounts for over 1 million diagnoses and half a million deaths per 
year, which is equivalent to approximately 8% of cancer-related deaths world-
wide. This review will discuss several factors of colorectal cancer, including risk 
factors, genes involved, incidence, and mortality. 
 
DNA DAMAGE AND CRC 
Like all cancers, CRC can be initiated by DNA damage. This damage is usually 
induced by chemical agents, smoking, alcohol consumption, or other factors. 
Cells possess precise and effective DNA repair mechanisms in order to prevent 
an accumulation of such cell damage. Of the most prominent DNA repair path-
ways, specifically for oxidative DNA lesions, is the base excision repair (BER) 
 2 
pathway. This pathway recognizes and repairs base modifications and single 
strand breaks. BER is initiated by a mono- or bifunctional DNA glycosylase and 
involves 4 majors steps. The first is base lesion recognition, excision and cleav-
age of an abasic site. The second step involves end processing of single strand 
break termini in order to generate 3’ hydroxyl/5’ phosphate group ends. The next 
step is gap-filling after lesion excision, and the final step involves nick sealing by 
DNA ligases. There are three key human proteins involved in the BER and SSB 
repair pathways: X-ray repair cross-complementing protein 1 (XRCC1), 8-ox-
oguanine DNA-glycosylase 1 (OGG1), and apurinic endonuclease 1 (APE1). 
XRCC1 acts as a scaffold to recruit BER proteins, OGG1 helps generate SSBs 
with3’ P αβ unsaturated aldehyde and 5’ P termini, and APE1 is a key enzyme 
responsible for the incision of the apurinic/apyrimidinic sites as well as the gener-
ation of the 3’-OH termini. (1) 
 
STAGES OF COLORECTAL CANCER 
Like all carcinomas, colorectal cancer is classified by stages. The most com-
monly used staging system for colorectal cancer is the TNM system, which has 
been established by the American Joint Committee on Cancer. (2) This system 
looks at three key factors to determine the stage of cancer: Tumor (T), Lymph 
node, (N), and Metastasis (M). T looks at how far the primary tumor has grown 
into the wall of the colon or rectum, and whether or not it has expanded into sur-
rounding areas. N measures the extent of which the cancer has spread to nearby 
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lymph nodes, and M distinguishes whether the cancer has spread, or metasta-
sized, to other parts of the body, such as the liver, lungs, or brain. Each factor is 
given a score ranging from 0-4, with 0 being the least severe and 4 being the 
most. Once each factor is scored, then the cancer’s overall stage is determined. 
Staging is important for exploring treatment options. With that in mind, we can 
now list the stages of colorectal cancer, and the severity of each of the aforemen-
tioned factors that characterizes each stage. All stage descriptions and TNM 
characterizations were gathered from the Cancer Treatment Centers of America. 
A visual representation of the progressing stages of colorectal cancer can be 
seen in the figure above (credit: SurgeryToday.com) 
Figure 1: Stages of Colorectal Cancer 
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Stage 0, the earliest and least severe stage, is also known as carcinoma in situ 
or intramucosal carcinoma. At this point, the cancer has not grown beyond the in-
ner layer of the colon or rectum. A diagnosis of stage 0 colorectal cancer coin-
cides with the following TNM categories: 
 Tis: The cancer has not grown beyond the lining of the colon or rectum 
 N0: The cancer has not spread to any lymph nodes 
 M0: there has been no spreading to organs or other areas 
 
If colorectal cancer has been diagnosed as Stage I, it means that the cancer has 
grown through the muscular mucosa and into the submucosa, or it may have 
also grown into the muscular propria. However, the cancer has not spread to 
nearby lymph nodes or distant sites. 
  T1-T2: the cancer is considered T1 if it has grown through the mus 
  cular mucosa and into the submucosa. If it has grown into the mus 
  cular propria, then it is T2  
  N0 
  M0 
 
At Stage II, colorectal cancer is divided into three subcategories: IIA, IIB, and IIC. 
The difference between these categories is the extent to which the cancer has 
spread. 
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Stage IIA (T3, N0, M0): The cancer has grown into the outermost layers of the 
colon or rectum but has not grown through them. It has not reached nearby or-
gans or lymph nodes and has not spread to distant  organs. 
Stage IIB (T4a, N0, M0): The cancer has grown through all of the layers  of the 
colon or rectum but has not grown into other organs or tissues. 
Stage IIC (T4b, N0, M0): The cancer has grown through all of the layers of the 
colon or rectum and has grown into nearby organs or tissues. The cancer has not 
spread to the lymph nodes or distant organs. 
 
By Stage III, the cancer has begun to spread into the lymph nodes. Like stage II, 
this stage is again categorized into three separate categories: IIIA, IIIB, and IIIC. 
The difference between categories is how far the cancer has spread, and how 
many lymph nodes are affected. 
Stage IIIA: The cancer has grown into the submucosa. It may have also grown 
into the muscularis propria. The cancer has spread to 1 – 3 lymph nodes near 
the site of the primary tumor but has not spread to distant sites. On the TNM 
scale, Stage IIIA colorectal cancer can be staged in two different ways: 
T1- T2: If the cancer has grown into the submucosa it is considered T1. Cancer 
that has grown into the muscularis propria is categorized as T2. 
N1a- N1b: The cancer has spread to 1 – 3 nearby lymph nodes. N1a indicates 1 
lymph node, while N1b indicates 2 – 3. 
M0: The cancer has not spread to distant organs. 
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OR 
T1: The cancer has grown into the submucosa. 
N2a: the cancer has spread to 4-6 nearby lymph nodes 
M0: The cancer has not spread to distant organs 
 
Stage IIIB: The cancer has grown into the outermost layer of the colon or rectum, 
but has not reached nearby organs. Or, it has grown through the wall of the colon 
or rectum and into nearby organs or tissues. The cancer has spread to 1 – 3 
lymph nodes near the primary site, but has not spread to distant organs. Stage 
IIIB can be categorized in three different ways: 
T3-T4a: The cancer has grown through the muscularis propria and into the 
outermost layers of the colon or rectum, but not all the way through them (T3). 
Or, the cancer has grown through the visceral peritoneum, the outermost lining of 
the intestines (T4a). 
N1a- N1b: The cancer has spread to 1 – 3 nearby lymph nodes. N1a indicates 1 
lymph node, while N1b indicates 2 – 3. 
M0: The cancer has not spread to distant organs. 
OR 
T2-T3: The cancer has grown through the submucosa (T2), or the cancer has 
grown through the muscularis propria and into the outermost layers of the colon 
or rectum, but not all the way through them (T3). 
N2a: Cancer cells have been located in 4 – 6 lymph nodes in the nearby region. 
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M0: The cancer has not spread to distant organs. 
OR 
T1-T2: If the cancer has grown into the submucosa it is considered T1. Cancer 
that has grown into the muscularis propria is categorized as T2. 
N2b: Cancer cells have been located in more than 7 lymph nodes in the nearby 
region. 
M0: The cancer has not spread to distant organs. 
 
If colorectal cancer is diagnosed as Stage IIIC, the cancer may or may not have 
grown through the wall of the colon or rectum but has spread to four or more 
lymph nodes near the primary site. The cancer has not metastasized to distant 
sites. Like Stage IIIB, Stage IIIC cancers can be categorized in three separate 
ways: 
T4a: The cancer has grown through the visceral peritoneum, the outermost lining 
of the intestines. 
N2a: Cancer cells have been located in 4 – 6 lymph nodes in the nearby region. 
M0: The cancer has not spread to distant organs. 
OR 
T3-T4a: The cancer has grown through the muscularis propria and into the 
outermost layers of the colon or rectum, but not all the way through them (T3). 
Or, the cancer has grown through the visceral peritoneum, the outermost lining of 
the intestines (T4a). 
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N2b: Cancer cells have been located in more than 7 lymph nodes in the nearby 
region. 
M0: The cancer has not spread to distant organs. 
OR 
T4b: The cancer has grown through the wall of the colon or rectum and has 
extended into nearby tissues or an other organ. 
N1-N2: It has spread to at least 1 lymph node, but no more than 6. 
M0: The cancer has not spread to distant organs. 
 
The most advanced stage of colorectal cancer is stage IV. At this stage, the can-
cer has metastasized to distance sites, such as the liver or lungs. The cancer 
may or may not have grown through the wall of the colon or rectum, and lymph 
nodes may or may not have been affected. Because of this, Stage IV colorectal 
cancer can be defined by any T or N category, with the only difference being 
whether an M1 or M2 assignment is more appropriate. M1 refers to a cancer that 
has spread to one different organ, and this type of cancer would be considered 
stage IVA. M2 classification is a cancer that has spread to more than one organ 
(stage IVB). 
 
PROGRESSION PATHWAYS OF COLORECTAL CANCER 
There are two known progression pathways to colorectal carcinoma. The first is 
the APC, LOH or MSS (Microsatellite Stable) Pathway, first described by Fearon 
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and Vogelstein in 1990. (3) This pathway, also known as the classic pathway, 
represents the adenoma-carcinoma sequence, and accounts for 60-80% of colo-
rectal adenocarcinomas. It begins with a bi-allelic mutation of the APC gene in a 
stem cell of the colonic mucosal crypt. The mutated crypt cell then produces a 
truncated version of the APC protein that lacks its critical function of sequestering 
Beta-catenin. Beta catenin is a protein involved in both cell to cell adhesion, and 
also a component of a growth promoting nuclear transcription factor. This mu-
tated stem cell then expands along the crypts basement membrane, onto the mu-
cosal surface and into non-neoplastic adjacent crypts. At this point, the adenoma 
is referred to as a microadenoma, and the cells that make up this neoplasm show 
an adenomatous phenotype or dysplasia. Each cell will have an identical APC 
gene mutation. 
 
The next step of the APC pathway is the formation of a tubular adenoma, a small 
dysplastic polyp. These polyps generally feature an up regulation of COX-2 en-
zyme activity, which inhibits apoptosis. For these polyps to increase in size, there 
may need to be a mutation of the oncogene K-ras. This mutation is frequently as-
sociated with alteration of the polyp architecture to tubulovillous or villous.  
  
High grade dysplasia in adenomas is the next step in this pathway. All adenomas 
show at least low-grade dysplasia. High grade dysplasia occurs when there is in-
creased nuclear atypic and extreme gland architectural abnormality. Examples of 
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this architectural abnormality include back to back glands and cribriform struc-
tures. In the APC pathway, high grade dysplasia has been found to be associ-
ated with p53 mutation. This mutation is believed to be the driving force for the 
transition from low grade to high grade dysplasia and invasive carcinoma. Fur-
thermore, in approximately 75% of colon cancers there is also a deletion of a 
specific region of chromosome 18q. This region contains the tumor suppressor 
gene DCC, and its deletion is also considered an important mutation in adenoma 
progression to cancer. SMAD2 and SMAD4, two other tumor suppressor genes 
that may possibly be affected by this deletion. 
  
The endpoint colorectal adenocarcinoma of the APC pathway is characterized by 
chromosomal instability (microsatellite stable) with numerous chromosomal 
breaks, losses and duplications (aneuploidy) and deletions of multiple genes 
(LOH). These colorectal adenocarcinomas are more frequently found in the distal 
colon and rectum, and their physical appearance may be flat, plaque-like, ulcer-
ated or polypoid. Histologically it is moderately differentiated.  
  
The second pathway, which accounts for 10-30% of colorectal adenocarcinomas, 
is the serrated polyp pathway. (4) This pathway  is characterized by a series of 
polyps containing glands or crypts with a characteristic saw-toothed, or serrated, 
outline. This pathway, like the APC pathway, begins with a mutation in a crypt 
stem cell. However, this activating mutation is in an oncogene belonging to the 
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RAS-RAF-MAP kinase intracellular signaling pathway. In most instances, the mu-
tated oncogene is BRAF, but there have also been instances where KRAS muta-
tions occur. Because this mutation activates a signaling pathway that controls 
growth and proliferation, the crypt cells adapt in a way that forestalls transfor-
mation. These changes result in a phenotypic alteration of the cells that repre-
sents a process called cell senescence and is quite distinct from the transformed 
appearance of the cells of the APC pathway. 
 
A sign of senescence in the aberrant crypt focus is that the crypts become en-
larged to accommodate colonocytes with normal sized nuclei but increased cyto-
plasmic volume. These colonocytes are also less likely to slough into the lumen. 
For cells with a BRAF mutation, there is marked serration of the crypts, and the 
cytoplasm is filled with small mucin vacuoles. In comparison, the KRAS mutated 
cells have less prominent serration but a noticeable tufting of the surface, and 
also show increased numbers of large goblet cells. Regardless of the mutation, 
both types of cells are considered hyperplastic, and are precursors of hyper plas-
tic polyps referred to as Microvesicular Serrated Polyp (BRAF mutation) or Gob-
let Cell Serrated Polyp (KRAS mutation). 
  
Both types of hyper plastic polyps are small, sessile or flat, and occur mainly in 
the distal colon and rectum. Due to them being quite common, for some time it 
was thought that these polyps had no role in cancer development. However, it 
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has now been shown that the BRAF mutation hyper plastic polyps, especially 
when located in the proximal colon, are likely to develop disordered growth and 
form into a sessile serrated adenoma. This adenoma can develop dysplasia over 
time to become a Dysplastic Serrated Polyp, and eventually develop into a can-
cer. 
  
The endpoint of the BRAF mutation serrated pathway frequently show Microsat-
ellite instability, but almost half show Microsatellite stability. The process that 
drives BRAF mutation serrated polyps to carcinoma is CpG-island methylation. 
The reason behind this is that these polyps are susceptible to aberrant methyla-
tion of the promotor regions of suppressor and mutator genes. The inactivation of 
growth control genes via this mechanism is possibly the reason for the break-
down in senescence, leading to the abnormal growth and dysplasia. Later on in 
this pathway, there is an inactivation of the mismatch repair gene hMLH1 due to 
a bi-allelic methylation of its promoter region. This inactivation leads to micro sat-
ellite instability, which further leads to a number of mutations, including in the ex-
ons of important growth control and apoptosis genes such TGF-RII and the BAX 
gene. The development of MSI in the serrated pathway appears to be analogous 
to the p53 mutation in the APC pathway and leads to high grade dysplasia and 
carcinoma. Compared to classical pathway carcinomas, BRAF mutated MSI ser-
rated carcinomas present on average a decade later, have a better prognosis 
and differ in their response to chemotherapeutic agents. On the other hand, 
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BRAF mutated MSS carcinomas have a significantly poorer prognosis than con-
ventional colorectal carcinomas. 
  
Compared to BRAF mutated serrated carcinomas, end-point KRAS mutated ser-
rated carcinomas tend to occur more distally. Additionally, they tend to have 
lower levels of CpG island methylation, are MSS, have a mutation in p53 and 
therefor morphologically resemble the classical pathway MSS carcinomas. 
 
GENES INVOLVED IN CRC 
Many genes have been found to be involved in CRC development, but the mo-
lecular mechanism underlying CRC development has not been fully determined. 
Also, how the genes relate to each stage of CRC has not been determined ei-
ther. A study, published in November 2017 (4), attempted to investigate CRC 
mechanism and CRC stage-related genes. The study found 493 intersection 
DEGs, including 128 common up-regulated DEGs and 365 common down-regu-
lated DEGs. A network of these DEGs can be seen in Figure 2 above. The study 
goes on to explain that in previous studies, BUB1B and MCM2 were found to be 
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up-regulated in CRC tissues when compared to healthy colorectal tissues, while 
ADH1B was found to be down-regulated. Figure 1 shows a map of the functional 
genes: triangles designate unregulated genes, while squares designate down 
regulated genes.  
CDC20, PTTG1 and MAD2L1 were gradually up-regulated in stage I, II, III, and 
IV CRC, and these genes were predicted to interact with BUB1B. UGT2B17 in-
teracted with ADH1B and was gradually down-regulated. MCM7 interacted with 
MCM2. BUB1B and MAD2, mitotic checkpoint proteins, bind to CDC20 and 
therefore compose the mitotic checkpoint complex. The Mitotic checkpoint com-
plex is able to inhibit the anaphase-promoting complex/cyclosome CDC20 medi-
ated securing degradation and anaphase onset. When there is an inappropriate 
over expression or under expression of these genes, there can be an alteration 
Figure 2: Map of Functional Genes with 
relation to CRC tissue. Triangles 
designate unregulated genes, while 
squares designate down regulated 
genes. 
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of mitotic checkpoint function that can result in improper anaphase like DNA an-
euploidy. Expression of CDC20 is high in CRC primary cancer tissues and even 
higher in metastatic liver tissues. The level of expression also correlates with clin-
ical stage and overall survival, making it a potential prognostic biomarker of CRC. 
PTTG1 is a signal transducer and an index mammalian securin, and its silencing 
can suppress HCT116 cell growth, colony formation, cell migration and invasion 
in vitro, and has been found to decrease tumor metastasis in nude mice. 
MAD2L1, a component of the colon-specific gene proliferation signature, is high 
expressed in actively cycling CRC cells and the proliferative compartment of co-
lon crypts. This study found a CRC stage-related gradual increase in the expres-
sions of BUB1B, CDC20, PTTG1, and MAD2L1 that agreed with previous stud-
ies, and they thought that this indicated that CDC20, PTTG1, and MAD2L1 might 
accelerate the development of CRC from stage I to stage IV by labilizing mitotic 
checkpoint system. 
Figure 3: Gene Expression in 
All Stages of CRC (5) 
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MCM7, which was found to be gradually up-regulated from stage I to stage IV 
CRC, was predicted to interact with MCM2. Both MCM7 and MCM2 are mini 
chromosome maintenance proteins, and they bind to chromosome at origins of 
DNA replication together with other proteins to start DNA replication. A classical 
characteristic of cancer is frequent, uncontrolled DNA replication, so it is easy to 
see how over expression of MCM7 would lead to tumorigenesis in the colon.  
  
UGT2B17 is a phase II detoxification UDP-glucuronosyltransferase enzyme, sig-
nificantly altered its expression in CRC samples of 4 stages and was predicted to 
interact with ADH1B. Both UGT2B17 and ADH1B participate in the KEGG path-
ways of “Chemical carcinogenesis”, “Drug metabolism - cytochrome P450” and 
“Metabolism of xenobiotics by cytochrome P450”. Also, the copy number varia-
tion of UGT2B17 is associated with CRC is, and UGT2B17 itself is a component 
of ColoGuidePro, an independent 7-gene prognostic signature for stage III CRC. 
For all of these reasons, believed to be a potential CRC stage-related gene, and 
it might expedite CRC development. 
 
Another study, conducted by Huo et all (6), focused on gene expression during 
each stage of colorectal cancer. The genes in particular they discussed were 
NEK4, RNF34, HIST3H2BB, HIST2H4A, NUDT6, LRCH4, and AMIGO2. NEK4 
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encodes NIMA related kinds 4, which is a serine/threonine protein kinase re-
quired for normal entry into replicative senescence. In cell cultures, it has been 
shown that suppression of NEK4 doubled the number of replications needed to 
reach senescence, reduced cellular reactions to double-stranded DNA damage 
in both the recruitment of repair proteins and arresting of further cell divisions, 
and also reduced activity of the p53 tumor suppressor protein. The results of Huo 
et all’s study suggested that the expression of NEK4 decreased the higher the 
stage.  
  
RNF34 encodes ring finger protein 34, was first characterized as hRFI (human 
ring finger homologous to inhibitor of apoptosis protein type) and has been 
shown to have anti-apoptotic properties. It has also been shown to play a role in 
p53 regulation via ubiquitination and subsequent proteosomal degradation. When 
overexpressed, RNF34 leads to the resistance of 5-fluorouracil-induced apopto-
sis in colorectal cancer cells via activation of NF-kappaB and up regulation of 
BCL-2 and BCL-XL. Like NEK4, Huo et all found that RNF34 expression was 
lower at higher stages of CRC.  
  
HIST3H2BB and HIST2H4A, both encoding histone proteins, increase in expres-
sion increasing cancer stages. When not undergoing replication, eukaryotic DNA 
is stored in a wrapped and coiled form around four pairs of histone proteins. 
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These histone proteins, which provide support, are also sensitive to post-transla-
tional modification, such as acetylation and deacetylation, which cells use to help 
regulate transcription. At this time, a direct link to the role of increased histone 
protein expression is not clear. 
  
Members of the NUDT6 gene family, which are down regulated across cancer 
stages, play roles that include controlling the level of cellular metabolites and sig-
naling compounds as well as degrading “potentially mutagenic” oxidized nucleo-
tides. The down regulation of these genes contributes to cancer cells ability to 
proliferate and grow.  
 
INCIDENCE AND MORTALITY RATES OF COLORECTAL CANCER 
 
For the past several decades, incidence and mortality rates have been declining 
for a number of reasons (decreased smoking, decreased consumption of red-
meat, increased use of aspirin, introduction of screening tests, and better 
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treatments.) Every 3 years, the American Cancer Society provides an update of 
CRC incidence, survival, and mortality rates and trends. 
 
Colorectal tumors can develop in 3 separate sites: the proximal colon, the distal 
colon, and the rectum. A small percentage of tumors can grow in other locations. 
The location of the tumor actually has an effect on its characteristics, responsive-
ness to drugs, and prognosis. The most common tumor site is the proximal co-
lon, followed by the rectum.  
Figure 5: Distribution of Colorectal Cancer Location by Age, US, 2009-2013 (7) 
Figure 4: Colorectal Cancer Incidence (2009–
2013) and Mortality (2010–2014) Rates by 
Race/Ethnicity and Sex, United States. (7) 
AI/AN indicates American Indian/Alaska Na-
tive; API, Asian American/Pacific Islander; 
NHB, non-Hispanic black; NHW, non-His-
panic white. Rates are age adjusted to the 
2000 US standard population. 
*Rates for AI/ANs are based on Contract 
Health Service Delivery Area (CHSDA) coun-
ties; incidence rates exclude data from Kan-
sas. 
Sources: Incidence: NAACCR, 2016. Alaska 
Natives only: SEER program, 2016. Mortality: 
NCHS, CDC, 2016. 
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However, as the graph below shows, there is great variation in the distribution of 
tumor site depending on sex and age. Though there are some consistencies: for 
example, the  
most common site of tumorigenesis in both men and women of 80+ years is in 
the proximal colon, and for men and women >50 years the most common site is 
the rectum. 
Although incidence and mortality rates have improved over the last several 
years, colorectal cancer is still a major health concern in the United States. Prior 
to 2017 there were projected to be 135,430 individuals newly diagnosed with 
CRC and 50,260 deaths from the disease over the course of the year. A majority 
of the cases occur in individuals aged 65+, but 45% of men and 39% of women 
are younger than age 65 years at diagnosis.  
 
RISK FACTORS FOR COLORECTAL CANCER 
Many studies have been done on the risk factors of colorectal cancer. In recent 
years, it has been shown that there is a significant connection between the gut 
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microbiota, diet and the risk of colorectal tumorigenesis. Inside and on the sur-
face of every human being is a complex and abundant grouping of various micro-
organisms. These organisms collectively make up what is referred to as the hu-
man microbiota. The majority of the microorganisms that make up the microbiota 
can be found in the gut. In fact, the human gastrointestinal tract is home to any-
where from 103 to 104 microorganisms. The human microbiota, specifically in the 
gut, plays a major role in many functions in the body, such as the fermentation of 
residual food, immune function, and protection against various pathogens. How-
ever, studies have shown that several environmental factors can lead to a 
change in the human microbiota, which is called dysbiotic microbiota. Dysbiotic 
microbiota has been shown to lead to various disease states such as Crohn’s 
disease and ulcerative colitis, which are collectively referred to as Inflammatory 
Figure 6: Various Risk 
Factors of Colorectal Cancer 
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Bowel Diseases (IBD). There are several theories as to why the microbiota fac-
tors into IBD. One theory is that there is an excessive immunologic response to 
normal microflora that is a result of a malfunction in the immune system. The the-
ory that coincides with the study in this grant is the suggestion that changes in 
the composition of gut microflora elicits pathological responses from the normal 
mucosal immune system. Therefore, although IBD is characterized by an abnor-
mal mucosal immune response, it is believed that microbial factors play an im-
portant role in this response.1 Obesity and metabolic syndromes have also been 
linked to the development of a dysbiotic microbiota. As a result of the role that 
the human microbiome has in various disease states, numerous studies have be-
gun into controlling and manipulating the human microbiota in order to alleviate 
symptoms of these various disease states.  
 
In terms of diet, there are several factors that are believed to increase or de-
crease one’s chance of developing CRC, due to various effects on the composi-
tion of the gut microbiota. A review published in 2016, conducted by Juan Tuan 
and Ying-Xuan Chen, (8) looked at three specific diet factors - fiber, red or pro-
cessed meat and alcohol - which were believed to have a significant role in CRC 
development. Their review spoke of how studies have shown a significant de-
crease in CRC risk in those individuals with increased intake of total dietary fiber. 
A proposed mechanism is that resistant starch is fermented by bacteria into 
short-chain fatty acids, specifically butyrate. These short-chain fatty acids have 
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an influence on inflammation factors tumor necrosis factor α and interleukin 6, 
and also suppress the transcription factor nuclear factor κB. Butyrate also plays 
an important role in the homeostasis of the epithelium of the colon. It does this by 
acting as a histone deacetylase inhibitor, directly affecting gene expression, and 
has also been shown to have anti-carcinogenic, anti-inflammatory, and anti-oxi-
dant functions. Butyrate also has an effect on cancer cells, enhancing apoptosis 
and suppressing proliferation. Compared to fiber-based diets, animal based di-
ets, which are high in fat and protein, have been associated with an increase in 
abundance of Bacteroidetes as well as a decrease in Firmicutes, which produce 
butyrate.  
 
The consumption of red or processed meat has also been linked with increased 
likelihood of developing CRC, as shown in figure 6 below. Processed meat, iden-
tified as a product obtained through several processes such as salting, curing, 
fermentation or smoking, has been classified as carcinogenic to humans, while 
red meat has been identified as probably carcinogenic to humans. A recent study 
Figure 7: Link between 
Processed and Red Meat 
and CRC. At this time, 
processed meat is 
officially classified as 
carcinogenic, while red 
meat is identified as most 
likely carcinogenic to 
humans 
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by Vulcan et all, published in Food & Nutrition Research, (9) found that “Beef in-
take was inversely associated with colon cancer. However, in men high intake of 
beef was associated with increased risk of rectal cancer. High intake of pork was 
associated with increased incidence of CRC, and colon cancer. Processed meat 
was associated with increased risk of CRC in men. Fish intake was inversely as-
sociated with risk of rectal cancer. No significant interactions were found between 
different types of meat and weight status.”  
The biological reasons for the association between red and processed meat and 
CRC is unclear at this time, but multiple molecular mechanisms have been pro-
posed, and an overview is shown in the figure below. The first involves heter-
ocyclic amines (HCAs). HCAs are chemical compounds generated in fish and 
meat when cooked at high temperatures. They are generated through the Mail-
lard reaction between free amino acids and sugars. The main HCAs found in 
cooked red meat are 2–Amino-3, 8-dimethyl imidazo-[4,5f] quinoxaline (MeIQx) 
Figure 8: Proposed 
links between red and 
processed meat and 
CRC 
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and the 2-Amino-1-methyl6 phenylimidazo [4,5b] pyridine (PhIP). Both of these 
compounds have been considered potentially carcinogenic in humans, and it is 
proposed that their levels are elevated in humans after consumption of cooked 
red meat. Several studies have shown that there is a strong connection between 
HCAs intake and CRC. (10). However, in the past conflicting results have been 
described, so more studies will need to be performed in order to clarify the link 
between HCAs and CRC. 
 
The second major proposed mechanism linking red meat consumption to CRC 
involves polycyclic aromatic hydrocarbons (PAHs). PAHs are substances pro-
duced by an incomplete combustion of inorganic compounds such as tobacco, oil 
and gas. With regards to red meat, PAHs are produced during procedures such 
as barbecuing, or when food is processed by smoking. Benzo[a]pyrene (BaP) is 
considered the principal carcinogenic PAH in humans. Studies have shown that 
human colon cells are able to metabolize PAHs. The aryl hydrocarbon receptor, 
a transcription factor that is activated by ligand like PAH, plays a critical role in 
the regulation of drug metabolizing enzymes, such as CYP1A1, CYP1A2, 
CYP1B1, glutathione S-transferase and UDP-glucoronyltransferase. These en-
zymes cause toxicity or carcinogenesis through the processing of the toxicants to 
reactive metabolites that, finally, interact with cellular macromolecules (e.g., DNA 
adducts). However, like HCAs, more studies are needed to determine a clear link 
between ingestion of BaP, and other PAHs, and CRC. 
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The next three mechanisms proposed between red meat consumption and CRC 
risk all revolve around heme. (11) Heme is the prosthetic cluster of myoglobin 
and hemoglobin, and elevated concentrations are responsible for the red color of 
meat. The three mechanisms underlying the association between heme con-
sumption and CRC risk are as follows: i) the lipid –peroxidation; ii) the N-nitroso 
compounds (NOCs) formations; iii) the cytotoxicity.  
 
Heme iron possesses redox properties, and it takes part in free radical-generat-
ing reactions with the production of reactive oxygen species. These reactions, 
and subsequent ROS production, leads to oxidative DNA damage which is con-
sidered highly mutagenic. ROS are also involved in lipid peroxidation, a compli-
cated process which leads to the formation of cytotoxic and genotoxic aldehydes, 
which are able to promote cancer progression. 
 
Endogenous NOCs are formed by N-nitrosation process of amines and amides. 
They are considered important genotoxins because they are able to induce muta-
tions in DNA. Unlike exogenous NOCs, which humans are exposed to from 
sources such as tobacco products, occupational environments and drugs, endog-
enous NOCs are generated by the reaction of nitrite with the products of amino 
acid degradation in the stomach. These kind of NOCs make up 75% of the total 
NOC exposure. Many studies have shown a strong link between endogenous 
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NOCs and CRC. N-alkyl-NOCs can induce transitions of DNA’s bases (GC to 
AT) in genes mutated in human tumors. Also, presence of nitrosyl heme, which is 
formed by a nitrosylation or nitrosation in ileum and in faeces, might promote the 
formation of extremely reactive alkylating agents like diazoacetate. As a conse-
quence, this process ends up in the formation of the NOC DNA adduct, named 
O6-carboxymethyl-2′-deoxy-guanosine (O6CMeG). This compound has been 
wide studied by Lewin et al., as carcinogenetic agent for CRC.  
 
Finally, a few studies have been conducted on animal models and shown that 
heme is able to augment the citoxicity of colon cells, which results in an in-
creased epithelial proliferation and afterward to cancer occurring. However, there 
have not been enough studies to confirm this proposed hypothesis. 
 
Red meat is enriched in glycan’s containing a variant of silica acid, the N-glycol-
ylneuraminic acid (Neu5G). This molecule is not naturally found in human tissues 
and is therefore only introduced by diet regimens containing pork, beef, and 
lamb. It has been suggested that humans can metabolically incorporate and ex-
press Neu5Gc into cell surface glyco-conjugates, and that the incorporation of 
Neu5Gc into human tissue could be involved in tumor initiation and progression. 
Neu5Gc-containing glycans act as “xeno-autoantigens” that may be targeted by 
naturally circulating anti-Neu5Gc “xeno-autoantibodies”. This process ends up in 
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development of xenosialitis, an inflammatory disease that influences cancer for-
mation and progression. (11) 
 
Understandably, another risk factor for CRC is excess body weight. Studies have 
shown that being overweight or obese increases ones risk of developing CRC. 
(12) It is believed that excess body weight leads to changes in the immune and 
endocrine systems, which in turn leads to pro-inflammatory adipokine levels. 
Overweight individuals are 9% more likely to develop CRC, while obese individu-
als are 19% more likely, compared to individuals of normal weight. Studies have 
shown that the carcinogenic effect of excess weight differs among cancer sites 
and gender. The risk associated with colon cancer was higher for colon cancer 
than rectal cancer and was higher in men than in women. However, abdominal 
adiposity has a strong association with colon cancer in both men and women.  
  
There have been several proposals as to the mechanisms that link adiposity to 
CRC risk. These proposed mechanisms include obesity-related insulin re-
sistance, hyperinsulinemia, sustained hyperglycemia, oxidative stress, adipocyto-
kine production and hyperinsulinemia-related increase of insulin-like growth fac-
tor-1. All of these are responsible for cancer promoting effects, favoring tumor 
growth, increasing cell migration, and ultimately leading to metastasis.  
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To further understand how obesity is believed to increase the risk of CRC, one 
must first understand the biology of adipose tissue. There are two different kinds 
of adipose tissue, white and brown. White adipose tissue is known to produce cy-
tokines and chemokine that induce inflammation, while brown adipose tissue’s 
primary function is to produce head. While there is belief that brown adipose tis-
sue could play a role in protecting against obesity, an accumulation of white adi-
pose tissue, especially in the abdominal cavity, is associated with increased insu-
lin resistance, lipolysis and inflammatory cytokine expression.  
  
As adipose tissue expands, the vasculature becomes unable to adequately oxy-
genate the adipocytes. The resulting hypoxia and oxidative stress lead to the 
overproduction of cytokines in obesity. Hypoxia initiates an inflammatory/angio-
genic response similar to that operating in tumor growth. Adipocyte hypertrophy 
also generates cellular metabolic and structural changes leading to endoplasmic 
reticular stress that stimulates the production of adipokines via activation of nu-
clear factor κB.  
  
At this time, there are four adipocyte-secreted hormones that are most relevant 
to colorectal tumorigenesis: adiponectin, leptin, resistin, and ghrelin. Adiponectin 
is an adipose tissue-derived protein, exclusively secreted from adipocytes. Its 
roles include stimulating insulin secretion, as well as increasing fatty acid com-
bustion and energy consumption. Studies have shown that there is an inverse 
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correlation between adiponectin levels and IR and visceral obesity. Therefore, it 
has been proposed that adiponectin plays a protective role against several malig-
nancies, including CRC. Because colon epithelium expresses both AdipoR1 and 
AdipoR2, both isoforms of the adiponectin receptor, there are two ways in which 
adiponectin can play this proposed protective role. Adiponectin may directly af-
fect cancer cells by affecting signal pathways involved in cell growth and prolifer-
ation or may indirectly affect them by altering hormone and cytokine levels, thus 
regulating whole-body insulin sensitivity. 
  
Leptin is a product of the Ob gene produced primarily by fat cells. It plays a major 
role in the control of food intake and energy expenditure, and has been proven to 
be able to regulate cell proliferation in various normal and neoplastic cell types. 
In colorectal cancer, leptin acts as a potent mitogen and antiapoptotic cytokine, 
and promotes the invasiveness of familial adenomatous colonic cells. As tumor-
igenesis progresses, leptin expression has been seen to be elevated. Leptin ex-
pression also dramatically increases from normal colonic mucosa to adenoma 
and adenocarcinoma, suggesting its involvement in multistep colorectal carcino-
genesis. Leptin is also capable to stimulating an angiogenic response in vitro in a 
manner similar to fibroblast growth factor 2. Thus, leptin plays an important role 
in the maintenance and regulation of vascular permeability in the adipose tissue. 
However, the effects of leptin on tumor angiogenesis have not been fully deter-
mined, although hypotheses have been raised. The most popular hypothesis is 
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that a paracrine stimulation of leptin-related local new blood vessel formation by 
leptin receptor-expressing endothelial cells and an effect similar to that of insulin-
like growth factor 1.  
  
Resistin is a protein belonging to the “resistin like molecules” (RELMs) family. It 
is produced by the stromovascular fraction of adipose tissue and peripheral blood 
monocytes. It is believed that a transient up regulation of resisting expression is 
important for accumulation of intracellular lipid content, which has been recently 
described as a potential factor in obesity-mediated IR, type 2 diabetes and in-
flammation. As such, it is believed that high resistin levels are related to cancer-
associated chronic inflammation. However, it’s role in colorectal carcinogenesis 
is still not fully determined. 
  
Ghrelin is an orexigenic peptide and represents an endogenous ligand for growth 
hormone secretagogue receptor type 1a. Ghrelin strongly stimulates growth hor-
mone release, modulates the secretion of other pituitary hormones, participates 
in glucose homeostasis, stimulates adipogenesis and chances the growth pro-
cesses of neoplastic tissues. In circulation, ghrelin exists in the circulation in two 
molecular forms: acylated and unacylated. The unacylated form predominates in 
circulation and is active in adipogenesis and neoplastic growth influencing prolif-
eration and apoptosis. Surprisingly, in different cancer cells ghrelin has been 
shown to act in either an antiapoptotic or apoptotic manner. Due to the fact that 
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ghrelin is a potent regulator of the GH/IGF-I axis, whose inappropriate regulation 
is known to be positively involved in colon cancer carcinogenesis, it is hypothe-
sized that ghrelin has a role in the development of colorectal neoplasms.  
 
Another well documented risk factor for colorectal tumorigenesis is inflammation, 
specifically inflammatory bowel disease (IBD). IBD is the collective name for mul-
tifactorial chronic relapsing inflammatory infections of the intestinal tract, which 
primarily includes Crohn’s disease and ulcerative colitis. As IBD develops, there 
is a change in the normal intestinal microbiota, a process called dysbiosis. The 
dysbiosis seen in patients with IBD is characterized by a reduction in both bacte-
rial quantity and bacterial diversity. In the context of IBD, microbiota analyses 
have negatively associated Faecalibacterium prausnitzii and Akkermansia mu-
niciphila with the disease, whereas Escherichia coli, Fusobacterium nucleatum, 
Haemophilus parainfluenzae, Veillonella parvula, Eikenella corrodens, and Ge-
mella moribillum were shown to be positively associated with the inflammatory 
disease. (13). Dysbiosis leads to a loss of epithelial barrier function and innate 
immunity of the intestinal tract, and these losses are fundamental to the patho-
genesis of inflammatory and infectious disease. In a healthy intestine, the epithe-
lium provides a distinct barrier critical to the homeostasis of the organ, while also 
being exposed to a myriad of environmental stimuli, such as microbes, dietary 
products and inorganic materials. The intestinal epithelium executes a compart-
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mentalization between the lumen and the host, simultaneously acting as a selec-
tively permeable first line of defense to fulfill its function of absorption, while 
maintaining an effective barrier against the intestinal microbiota, antigens and 
toxins. The epithelium also contributes to intestinal health through the production 
of mucous, via goblet cells, and the secretion of antimicrobial peptides via Pan-
eth cells. 
 
Inflammation can lead to carcinogenesis through several means: inducing gene 
mutations, inhibiting apoptosis or stimulating angiogenesis and cell proliferation. 
(14) Nuclear factor (NF)-κB has been identified as a major connection between 
inflammation and cancer. Mouse model studies have shown a dual role for NF-
κB in carcinogenesis, depending on the cell type. In enteroctyes, it contributes to 
tumor initiation by suppressing apoptosis. However, In myeloid cells it promotes 
tumor growth through the production of inflammatory mediators. Elevated NF-κB 
has also been shown to activate mutations in the Wnt pathway, which results in 
the differentiation of epithelial non-stem cells into tumor-initiating cells. The acti-
vation of NF-κB also results in the expression of inflammatory cytokines, such as 
tumor necrosis factor-alpha, interleukin-1, interleukin-8, and interleukin-8, as well 
as adhesion molecules, enzymes involved in prostaglandin synthesis, nitric oxide 
synthase, angiogenic factors and anti-apoptotic genes. All of these provide sur-
vival advantages to precancerous or tumor cells in the gut, allowing them to grow 
and proliferate.  
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Microbiota imbalances, especially in favor of pro-inflammatory opportunistic path-
ogens such as Enterobacteriaceae and Clostridium difficile, have been indicated 
to be involved in Tumor progression. Other bacteria that have been reported by 
support carcinogenesis by the induction of a pro-inflammatory response include 
Shigella, Citrobacter, Salmonella, Bacteroides fragilis, Fusobacterium, Strepto-
coccus gallolyticus and Clostridium septicum.  
 
Inflammation also acts as the major link between 3 factors in inflammation-asso-
ciated CRC: host immune response, intestinal microbiota and genotoxic events. 
There are several strains of bacteria in a healthy human microbiota that contain 
toxin-producing strains. It is not entirely determined how long-term exposure to 
low doses of such toxins contributes to the carcinogenic process. However, when 
dysbiosis leads to increased numbers of these bacteria, it can have disastrous 
effects. Toxins have a negative effect on key eukaryotic processes, such as cel-
lular signaling. Others directly attack the genome, and damage DNA either di-
rectly, via enzymatic attack, or indirectly, by provoking an inflammatory reaction 
that produces free radicals. Toxins can also have a negative effect on DNA repair 
mechanisms.  
 
For some time, B. fragilis toxin (BFT) has been proposed as on of the main CRC 
driving suspects due to many experiments. The capacity of BFT-producing 
 35 
strains to promote colon tumorigenesis is mediated by the increased expression 
of STAT3. This over expression leads to the recruitment of a subset of T helper 
type 17 lymphocytes that is highly pro-inflammatory, which suggests that the pro-
carcinogenic role of BFT is to promote a de-regulated inflammatory response. 
BFT is a metalloprotease which binds to colonic epithelial cells and stimulates 
the cleavage of E-cadherin. This increases intestinal barrier permeability and 
augments cell signaling via the beta-catenin/WnT pathway, which is activated in 
essentially all forms of CRC.  
 
  Although B. fragilis toxin has been shown to have a major role in colorectal car-
cinogenesis, recent studies have shown that the most actively transcribed toxins 
in tumor tissue and the surrounding mucosa of CRC patients are derived from E. 
coli, Salmonella enteric and Shigella flexneri. Because of these findings, it is be-
lieved that enterobacterial toxins have a strong role in tumorigenesis. Inflamma-
tion has also been seen to increase the number of toxigenic E. coli strains. E. coli 
strains are able to produce a wide variety of toxins, some of which have been 
shown to be harmful in humans, either by damaging DNA or disrupting cell sig-
naling. 
 
Another type of toxin that has been shown to increase tumorigenesis is the cy-
lolethal distending toxins (CDTs). These toxins comprise a family of intracellular-
acting bacterial protein toxins produced by several gram-negative bacteria. 
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These toxins have several effects on eukaryotic cells, the most characteristic be-
ing the induction of G(2)/M cell cycle arrest. There are three subunits that make 
up active CDTs: CdtA and CdtC, which guide internalization, and CdtB, which en-
zymatically induces DNA double-strand breaks that recruit and activate the ataxia 
telangiectasia mutated kinase, which triggers a DNA damage response. When 
exposed to sub-lethal levels of CDTs, cells have been shown to exhibit increased 
frequency of mutations, accumulation of chromosomal aberrations and enhanced 
anchorage-independent growth.  
 
Another group of toxins that is believed to play a role in CRC development in-
cludes those that disrupt the cell signaling that regulates cell proliferation or in-
duces inflammation. E. coli cytotoxic necrotizing factor 1 (CNF1), activates the 
Rho GTPases, inducing dysfunctions in already transformed epithelial cells, such 
as apoptosis counteraction, pro-inflammatory cytokines’ release, COX2 expres-
sion, NF-κB activation and boosted cellular motility. CNF1 also induces cells to 
enter the cell cycle and undergo DNA synthesis, while also interfering with nor-
mal cytokinesis. This leads to the production of multinucleate cells and in the on-
set of aneuploidia. Because it is known that cancer may arise when these regula-
tory pathways are interfered with, it has been proposed that CNF1-producing E. 
coli infections may contribute to tumorigenesis.  
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As to be expected, alcohol consumption is another risk factor of developing colo-
rectal cancer. In general, all drinkers have a 17% greater risk of developing colo-
rectal adenomas, compared to non-drinkers or those that occasionally consume 
alcohol. The idea is that several factors in the metabolism of ethanol lead to tu-
morigenesis. Intestinal bacteria have a high activity of alcohol dehydrogenase, 
which may oxidize ethanol in the colorectum, leading to a high level of acetalde-
hyde. Acetaldehyde is also produced from ethanol by CYP2E1. Acetaldehyde is 
further converted into acetic acid via aldehyde dehydrogenase, CYP2E1, or the 
combination of aldehyde oxidase and xanthine oxidase. When acetaldehyde is 
converted via CYP2E1, there is a production of reactive oxygen species, which 
furthermore add to carcinogenesis. Acetaldehyde is considered the most potent 
in colorectal carcinogenesis due to its interactions with various cellular and bio-
chemical processes (Rossi et all). (15) Alcohol metabolites have been shown to 
directly affect DNA stability. Acetaldehyde can bind to deoxynucleotides to from 
DNA adducts. DNA adducts can also be formed by malondialdehyde and 4-hy-
droxynoneal. In general, metabolic processes increasing ROS formation can in-
stigate direct DNA damage and encourage colorectal carcinogenesis. In fact, a 
2014 study showed that alcoholics formed more ethane-DNA adducts than non-
drinking controls (Linhart 16).     The metabolism of ethanol can be seen in Fig-
ure 8, provided by Rossi et all. (15) 
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Alcohol consumption, and specifically ethanol metabolism, has also been shown 
to affect colorectal carcinogenesis by indirectly affecting DNA stability. One such 
way that it does this is by influencing single-carbon metabolism. Normally, homo-
cysteine is converted to methionine via either methionine synthase or betaine ho-
mocysteine methyltransferase. Methionine adenosyl transferase then converts 
methionine to S-adenosylmethionine (SAMe). The methy groups from SAMe are 
then used by DNA methyltransferases to methylate deoxynucleotides. MTR, 
MAT, and DNMTs are all key enzymes in single-carbon metabolism that regulate 
DNA methylation. Ethanol and its metabolites all affect the activities of all of 
these enzymes. Specifically, alcohol and/or acetaldehyde reduce the activities of 
these enzymes, decreasing DNA methylation and dysregulates epigenetic pat-
terns. This decrease in DNA methylation has been seen in CRC.  
 
Figure 9: The Metabolism of 
Ethanol 
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Another way that alcohol consumption and subsequent ethanol metabolism indi-
rectly affects DNA is by interfering with folate metabolism, as can be seen in fig-
ure 9 below. Folate is first converted into tetrahydrofolate and then 510-methyl-
enetetrahydrofolate. 5,10-MTHF can then be used in the synthesis of DNA by 
participating in the conversion of dTMP from dUMP via thymidylate synthase. In 
addition, 5,10-MTHF can be further converted to 5-methyltetrahydrofolate by 
methylenetetrahydrofolate reductase. 5-MTHF is then used to produce methio-
nine, and therefore is involved in the production of SAMe. With regards to alcohol 
consumption and ethanol metabolism, acetaldehyde has been shown to have the 
ability to degrade folate, interfering with both DNA integrity and methylation.  
    
Alcohol intake has also been linked to affect other cofactor nutrients, such as vit-
amins B6 and B12, which are both important in DNA synthesis and methylation. 
Because chronic alcohol consumption can result in deficiencies in these vitamins, 
both of these processes would be affected. However, the levels of these vitamins 
can vary depending on the individual conditions and circumstances, so it is not 
absolutely certain that there is a link between alcohol consumption, vitamin lev-
els, and CRC risk. 
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Furthermore, alcohol may have a negative effect on DNA repair, although the ef-
fects at this time are controversial. Both nucleotide excision repair and base exci-
sion repair have been proposed to be involved in correcting alcohol-induced DNA 
damage. However, the findings so far have been significant, and more studies 
will need to be conducted to fully elucidate the effects of alcohol consumption on 
the mutations they can have on DNA repair mechanisms.  
 
Ethanol and its metabolites have also been shown to alter the levels of certain 
miRNAs, further affecting gene expression. Through this alteration, ethanol can 
indirectly affect processes such as lipid metabolism, epithelial to mesenchymal 
transition, angiogenesis, and the immune response, all of which can affect car-
cinogenesis. Some of the miRNAs than are affected by ethanol are miR-34a, 
miR-21, and miR-135. miR-34a is a known tumor suppressor, directly regulated 
Figure 10: Folate 
Metabolism 
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by p53. It is also a regulator of hepatic glucose, lipid, and drug metabolism, and 
has been shown to be down regulated in colorectal cancer cases. When its regu-
lation is affected, miR-34a usually leads to disorders such as obesity, 
dyslipidemia, and fatty liver disease. miR-21 is an oncogenic miRNA whose over 
expression has been associated with poor prognoses and lower overall survival 
counts in cases of CRC. It is involved with multiple cell signaling pathways, and 
increased levels can lead to an increase in NF-κB, leading to inflammation. Also, 
by modulating IL-10 and prostaglandin E2 production, and decreasing the 
amount of CD8+ T cells, miR-21 can further increase a carcinogenic immune 
state. miR-21 can also promote cell survival by down regulating the extrinsic 
apoptotic pathway, and increased levels increase β-catenin and SOX-2 expres-
sion, which leads to increased cancer cell stemness. miR-135, which has been 
shown to suppress APC, is decreased with ethanol exposure. It has also been 
shown to be a regulator of focal adhesion kinase, a protein tyrosine kinase that 
compromises epithelial barrier junctions and encourages cell motility. FAK also 
forms a signaling axis with VEGF, VEGFR2 and AKT to encourage angiogenesis, 
further facilitating tumorigenesis.  
 
Alcohol is also proposed to be able to modulate gene expression via alterations 
in histone modifications, especially histone 3. Studies on ethanol treated rats 
have shown ethanol-induced modifications in various histones in hepatocytes, 
which is consistent with the liver damage associated with alcohol consumption. 
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However, alterations in histone deacetylases have also been shown in CRC, so it 
is not a stretch to assume that the involvement of HDACs in alcohol induced co-
lon carcinogenesis is possible.  
 
Chronic alcohol intake can also lead to colorectal carcinogenesis by causing mu-
cosal inflammation of the intestine. One such mechanism that has been pro-
posed is an increased exposure to lipopolysaccharide. Ethanol consumption can 
increase both the production and exposure of LPS by inducing microbial dysbio-
sis and bacterial overgrowth. Ethanol has also been shown to increase the per-
meability of the intestinal barrier, further exacerbating LPS penetration and expo-
sure. This intestinal permeability can also be increased due the the oxidative 
stress caused by CYP2E1 metabolism of ethanol. In general, the oxidative stress 
caused by ethanol consumption and metabolism can increase intestinal wall per-
meability, and increased ROS production can also affect the barrier’s integrity. 
Recent studies have also shown that the colonic hyper permeability from alcohol 
is at least partly mediated via alcohol’s epigenetic effects on Notch1 via altered 
histone H3 deacetylation at the Notch1 locus. It has also been shown that etha-
nol can affect cellular β-catenin distribution by an inactivation of GSK3β. This can 
lead to both tumor production and aggression via production of MCP-1/CCR-2, 
and induction of cancer stem cell metastasis. Furthermore, the increase permea-
bility and exposure to LPS is sense by immune cells, which then increase ex-
pression of pro-inflammatory cytokine such as IL-6 and IL-18. The release of 
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these cytokines, coupled with the further release of ROS, leads to an inflamma-
tory cycle which promotes tumorigenesis. For example, alcohol exposure in mice 
can lead to an increase in M2b macrophage recruitment, which has been associ-
ated with a poor prognosis in colon cancer patients. (17). Another study has 
shown that chronic ethanol feeding in a azoxymethan/dextran sulfate sodium 
model of CRC in mice lead to an increase in cell proliferation and tumorigenesis. 
Furthermore, the authors discovered that alcohol induced release of pro-tumor-
igenic inflammatory cytokines, such as IL-1α, IL-6, and TNFα, was associated 
with an enhanced immune cell infiltration and colonic inflammation in their model. 
(18) Also, chronic alcohol consumption has been shown to accelerate polyposis 
in mice, and this enhance polyposis and submucosal invasion was associated 
with an increased mast cell infiltration in the submucosa. Alcohol consumption 
has also been shown to exacerbate intestinal inflammation by disrupting circa-
dian rhythms. Bishesari et all (19) wrote: “In a TS4Cre × APClow468 mouse model, 
we have shown that a diet including alcohol and a weekly 12 h phase reversal of 
light–dark cycles resulted in increased polyposis, along with an increased ratio of 
mMCP6+ mast cells to mMCP2+ mast cells in the intestinal tissue.” 
 
Consumption of red meat has also been found to suppress immune surveillance 
of tumors, change the composition of bile acids and induce the expression of 
liver cytochrome P-450 enzymes. (20) In 2016, Jayasekra et al. (21) concluded 
that alcohol intake is associated with an increased risk of KRAS mutated and 
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BRAF wildtype/KRAS wild type tumors originating via the traditional adenoma-
carcinoma pathway but not with BRAF mutated tumors originating via the ser-
rated pathway. 
 
Another significant risk factor of colorectal cancer is family history. On average, 
first degree relatives of colorectal cancer cases have an approximate two-fold 
risk of the disease compared to those without a family history. (22) Risk of CRC 
was higher when the relative was diagnosed at an earlier age. CRC risk also de-
pended on the age of the person at risk: people with positive family history in 
their 30s or 40s demonstrated a higher relative risk compared to their age-
matched peers than people with the same positive family history at an older age. 
(23) Knowledge of family history is important when it comes to screening. Most 
organizations recommend screening average-risk individuals for CRC beginning 
at 50 years of age. However, for those with greater risk, it is recommended to 
begin screening earlier, and screen more frequently. Individuals who have a first-
degree relative with hereditary nonpolyposis colorectal cancer should begin co-
lonoscopy at 25 years of age and repeat colonoscopy every one to two years. In 
persons with a family history of adenomatous polyposis syndromes, screening 
should begin at 10 years of age or in a person’s mid-20s (this is not clear), and 
repeat colonoscopy is typically required every one to two years. (24) A study by 
Schoen et all (25) looked to evaluate the effect of family history of CRC incidence 
and mortality after age 55, when the risk of early onset cancer had passed. With 
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regards to incidence, they “observed a modest 30% increased risk in CRC inci-
dence and mortality in subjects over age 55 with a family history of CRC in a first 
degree relative (FDR). Subjects with two first degree relatives with CRC were 
identified as a high-risk group, with a 2-fold increased risk of incident CRC. 
Within our age cohort, after excluding subjects with ≥2 FDR, a young age of on-
set in the FDR (<60 years at time of diagnosis) was not associated with a differ-
ential increased risk in CRC incidence or mortality compared to subjects with first 
degree relatives affected at older ages. We observed no difference in the risk re-
lationships between a family history of CRC and incident CRC in men compared 
to women. Nor did we observe a stronger relationship between a family history of 
colorectal cancer and proximal as opposed to distal cancer or colon as opposed 
to rectal cancer.” In terms of mortality, they found that “CRC mortality occurred in 
25.7% of incident cases (538/2090), limiting statistical power relative to cancer 
incidence. A family history of CRC was associated with an increase in CRC mor-
tality (HR=1.31), similar in magnitude to the increased risk observed for CRC in-
cidence, suggesting a limited impact of lead time or over diagnosis bias to our 
conclusions.” 
 
Like many other cancers, smoking is another risk factor for colorectal cancer. It 
was added to the list of smoking-attributable cancers by the International Associ-
ation for Research on Cancer in 2009, and by the US Surgeon General in 2014. 
Recent studies have shown that the relationship between smoking and colorectal 
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cancer incidence is most likely dependent on dose. For smokers who consumed 
for more than 30 pack-years or more than 20 cigarettes per day, the risks of CRC 
were increased by 34% or 46%, respectively. Also, the association between the 
two seems strangers for three phenotypes of CRC: micro satellite instability high, 
CpG island methylator phenotype high and BRAF mutation positive. 
 
Studies have shown that current and former smokers had increase risk of colo-
rectal cancer than nonsmokers, and this risk was found to be higher in men than 
women. The risks of CRC on male current smokers and former smokers are 38% 
and 23% higher than those on never smokers, respectively. Yet, the effect is 
much lower among women who are currently smoking (nonsignificant increase) 
or who were former smokers (18%).  Current smokers were more likely to be di-
agnosed with colorectal cancer at a younger age compared to former smokers. 
Also, it appears that the association of smoking with rectal cancer appears to be 
stronger than that of colonic cancer. Studies have also shown that cigarette 
smoking leads to higher CRC mortality as well.  
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CONCLUSION 
Despite incidence and mortality rates declining due to improved screening tech-
nology and guidelines, colorectal cancer is still a significant health risk.  Despite 
all advances in treatment and screening, CRC is still the third most prevalent 
cancer in the world. With all of this considered, the current and future research 
into what genes are involved in colorectal carcinogenesis, as well as risk factors, 
is incredibly important.  
 
As a relatively new topic of study, the gut microbiota will be very important to the 
study of colorectal cancer. The composition of an individual’s gut bacteria has 
been discovered to play a major role in their health, for good or for bad. If one is 
able to able to find a way to better control any dysbiota, it could go a long way to 
preventing inflammatory diseases of the gut, and, by extension, colorectal carcin-
ogenesis. 
 
On a similar note, diet has a major effect on the health of the intestine, and more 
work should be put into diet education. Certain diets, especially those adopted in 
western countries, are high in fat and protein, low in fiber, and very conducive to 
the development of adenomas. Public health initiatives should be put in place to 
warn the public of the dangers of such diets, and the importance of a healthy, 
balanced food intake. This also extends to harmful lifestyle choices such as 
smoking and alcohol consumption, which have been shown to cause damage 
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and carcinogenesis not just in the colon and rectum, but also in other parts of the 
body.  
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